Cargando…

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target

SIMPLE SUMMARY: Anaplastic lymphoma kinase (ALK) is a tyrosine kinase associated with Anaplastic Large Cell lymphoma (ALCL) through oncogenic translocations mainly NPM-ALK. Chemotherapy is effective in ALK(+) ALCL patients and induces remission rates of approximately 80%. The remaining patients do n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andraos, Elissa, Dignac, Joséphine, Meggetto, Fabienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795840/ https://www.ncbi.nlm.nih.gov/pubmed/33466277 http://dx.doi.org/10.3390/cancers13010144

Ejemplares similares

Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination
por: Colomba, A, et al.
Publicado: (2011)

Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas
por: Hoareau-Aveilla, Coralie, et al.
Publicado: (2017)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma
por: Fuchs, Steffen, et al.
Publicado: (2019)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
por: Sorrentino, Domenico, et al.
Publicado: (2020)

From circRNAs to fusion circRNAs in hematological malignancies
por: Babin, Loelia, et al.
Publicado: (2021)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas
por: Kuravi, Sudhakiranmayi, et al.
Publicado: (2019)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma
por: Krumbholz, Manuela, et al.
Publicado: (2018)

NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
por: Pearson, Joel D., et al.
Publicado: (2012)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein()
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

Generation of full-length circular RNA libraries for Oxford Nanopore long-read sequencing
por: Fuchs, Steffen, et al.
Publicado: (2022)

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
por: Brenner, Annette K., et al.
Publicado: (2021)

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
por: Daugrois, Camille, et al.
Publicado: (2021)

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
por: Chen, Yingyu, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy
por: Buetti-Dinh, Antoine, et al.
Publicado: (2016)

A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA
por: Gourvest, Morgane, et al.
Publicado: (2021)

Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis
por: Redl, Elisa, et al.
Publicado: (2020)

The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
por: Pearson, Joel D, et al.
Publicado: (2012)

Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
por: Shang, Chuquan, et al.
Publicado: (2023)

Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1
por: Chae, Hee-Sung, et al.
Publicado: (2016)

Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein
por: Kourentzi, Katerina, et al.
Publicado: (2020)

The EML4-ALK oncogene: targeting an essential growth driver in human cancer
por: MANO, Hiroyuki
Publicado: (2015)

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas
por: Pina-Oviedo, Sergio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ome7hoakt86rkj0kanssq6g517